Solventum (NYSE:SOLV) & AxoGen (NASDAQ:AXGN) Head-To-Head Contrast

AxoGen (NASDAQ:AXGN) and Solventum (NYSE:SOLV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Earnings & Valuation

This table compares AxoGen and Solventum”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21 million	15.00	-$15.70 million	($0.65)	-87.04
Solventum	$8.32 billion	1.79	$1.56 billion	$0.89	98.90

Solventum has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AxoGen and Solventum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AxoGen	-11.96%	-5.35%	-4.41%
Solventum	1.91%	25.03%	8.65%

Insider and Institutional Ownership

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

AxoGen has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Solventum has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AxoGen and Solventum, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1	2	13	0	2.75
Solventum	1	4	9	0	2.57

AxoGen presently has a consensus target price of $57.92, indicating a potential upside of 2.37%. Solventum has a consensus target price of $90.27, indicating a potential upside of 2.55%. Given Solventum’s higher probable upside, analysts plainly believe Solventum is more favorable than AxoGen.

Summary

Solventum beats AxoGen on 8 of the 14 factors compared between the two stocks.

About AxoGen

AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.

About Solventum

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.